Ocaliva, Erbitux and Vectibix sales and marketing update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Ocaliva obeticholic acid from Intercept to treat primary biliary cholangitis (PBC). Specifically, NICE recommended Ocaliva's use in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

The oral farnesoid X receptor (FXR; NR1H4) agonist has conditional approval in the EU for the indication. Ocaliva has accelerated approval in the U.S. to treat PBC...